Lenacapavir: a potential game changer for HIV prevention in the Americas, if the game is played equitably

作者：Valeria D Cantos, Brenda Crabtree‐Ramírez, Colleen F. Kelley, Carlos del Rı́o, Beatriz Grinsztejn · 发表于：The Lancet Regional Health - Americas · 年份：2025 · DOI：10.1016/j.lana.2025.101146 · 被引用次数：9 · 研究领域：HIV/AIDS Research and Interventions、HIV Research and Treatment、HIV/AIDS drug development and treatment

Lenacapavir, a first in class long-acting capsid inhibitor has near 100% efficacy in preventing HIV. As such, it has the potential to curb the rising HIV incidence in Latin America, a region with stark intra- and inter-country PrEP uptake disparities. In this viewpoint, we summarize the current efforts to scale up lenacapavir access globally and the necessary steps to include Latin America in these endeavours.